Digoxin-Inactivating Bacteria: Identification in Human Gut Flora
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Digoxin, the most widely used cardiac glycoside, undergoes significant metabolic conversion in many patients to cardioinactive metabolites in which the lactone ring is reduced. This appears to occur within the gastrointestinal tract. An attempt was made to isolate and identify the organisms capable of reducing digoxin from stool cultures obtained from human volunteers. Of hundreds of isolates studied, only Eubacterium lentum , a common anaerobe of the human colonic flora, converted digoxin to reduced derivatives. Such organisms were also isolated in high concentrations from the stools of individuals who did not excrete these metabolites when given digoxin in vivo. When the growth of E. lentum was stimulated by arginine, inactivation of digoxin was inhibited. Neither the presence of these organisms alone nor their concentration within the gut flora appeared to determine whether digoxin would be inactivated by this pathway in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“neither the presence nor the abundance of this species predicts digoxin reductions64–66. This discrepancy appears to be driven by strain-level variations in the E. lenta population67.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [64]
Citations
Cites
Human Fecal Flora: The Normal Flora of 20 Japanese-Hawaiians
Moore, W. E. C., & Holdeman, L. V. (1974) · Applied Microbiology · doi:10.1128/am.27.5.961-979.1974 · Cited by 1,144
Effect of diet on human fecal flora: comparison of Japanese and American diets
Finegold, S. M., Attebery, H. R., & Sutter, V. L. (1974) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/27.12.1456 · Cited by 518
Inactivation of Digoxin by the Gut Flora: Reversal by Antibiotic Therapy
Lindenbaum, J., Rund, D. G., Butler, V. P., Tse-Eng, D., & Saha, J. R. (1981) · New England Journal of Medicine · doi:10.1056/nejm198110013051403 · Cited by 423
Self-citationFecal microbial flora in Seventh Day Adventist populations and control subjects
Finegold, S., Sutter, V., Sugihara, P., Elder, H., Lehmann, S., & Phillips, R. (1977) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/30.11.1781 · Cited by 187
Fecal bacteriology of colonic polyp patients and control patients.
Finegold, S. M., Flora, D. J., Attebery, H. R., & Sutter, V. L. (1975) · PubMed · Cited by 137
Digoxin Metabolism in Patients
Peters, U. (1978) · Archives of Internal Medicine · doi:10.1001/archinte.1978.03630320018009 · Cited by 84
Unusually large digitalis requirements
Luchi, R. J., & Gruber, J. W. (1968) · The American Journal of Medicine · doi:10.1016/0002-9343(68)90049-1 · Cited by 78
Urinary excretion of reduced metabolites of digoxin
Lindenbaum, J., Tse-Eng, D., Butler, V. P., & Rund, D. G. (1981) · The American Journal of Medicine · doi:10.1016/0002-9343(81)90260-6 · Cited by 73
Self-citationDIHYDRODIGOXIN: A COMMON METABOLITE OF DIGOXIN IN MAN
CLARK, D. R., & Kalman, S. M. (1974) · Drug Metabolism and Disposition · doi:10.1016/s0022-5347(24)07322-1 · Cited by 65
Arginine, a growth-limiting factor for Eubacterium lentum
Sperry, J. F., & Wilkins, T. D. (1976) · Journal of Bacteriology · doi:10.1128/jb.127.2.780-784.1976 · Cited by 61
Research works printed but not linked: 4
- Clark, D. R., Drug Metab. Dispos. 2: 148 (1974).
- Portius, H. J., Arzneim.-Forsch. (Drug Res.) 14: 1073 (1964).
- Butler, V. P., J. Pharmacol. Exp. Ther. 221: 123 (1982).
- Finegold, S. M., Cancer Res. 35: 3407 (1975).
Cited by
Microbiota in health and diseases
Hou, K., Wu, Z.-X., Chen, X.-Y., Wang, J.-Q., Zhang, D., Xiao, C., Zhu, D., Koya, J. B., Wei, L., Li, J., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00974-4 · Cited by 3,171
Role of the normal gut microbiota
Jandhyala, S. M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i29.8787 · Cited by 3,001
Chemical transformation of xenobiotics by the human gut microbiota
Koppel, N., Maini Rekdal, V., & Balskus, E. P. (2017) · Science · doi:10.1126/science.aag2770 · Cited by 1,080
The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism
Spanogiannopoulos, P., Bess, E. N., Carmody, R. N., & Turnbaugh, P. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.17 · Cited by 717
Predicting and Manipulating Cardiac Drug Inactivation by the Human Gut Bacterium Eggerthella lenta
Haiser, H. J., Gootenberg, D. B., Chatman, K., Sirasani, G., Balskus, E. P., & Turnbaugh, P. J. (2013) · Science · doi:10.1126/science.1235872 · Cited by 704
Gut microbiome interactions with drug metabolism, efficacy, and toxicity
Wilson, I. D., & Nicholson, J. K. (2017) · Translational Research · doi:10.1016/j.trsl.2016.08.002 · Cited by 656
The Gut Microbial Endocrine Organ: Bacterially Derived Signals Driving Cardiometabolic Diseases
Brown, J. M., & Hazen, S. L. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-060513-093205 · Cited by 438
“With relevance to cardiovascular disease, the drug digoxin can be metabolized by a common actinobacteria, functionally inactivating the drug (81).”
BackgroundGut microbiota, a new frontier to understand traditional Chinese medicines
Feng, W., Ao, H., Peng, C., & Yan, D. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.02.024 · Cited by 377
Vinarov, Z., Abdallah, M., Agundez, J. A. G., Allegaert, K., Basit, A. W., Braeckmans, M., Ceulemans, J., Corsetti, M., Griffin, B. T., Grimm, M., et al. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105812 · Cited by 359
The Intestinal Metabolome: An Intersection Between Microbiota and Host
Ursell, L. K., Haiser, H. J., Van Treuren, W., Garg, N., Reddivari, L., Vanamala, J., Dorrestein, P. C., Turnbaugh, P. J., & Knight, R. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.03.001 · Cited by 355
The gut microbiome: an orchestrator of xenobiotic metabolism
Collins, S. L., & Patterson, A. D. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.12.001 · Cited by 348
Advancing functional and translational microbiome research using meta-omics approaches
Zhang, X., Li, L., Butcher, J., Stintzi, A., & Figeys, D. (2019) · Microbiome · doi:10.1186/s40168-019-0767-6 · Cited by 340
Microbiome therapeutics — Advances and challenges
Mimee, M., Citorik, R. J., & Lu, T. K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.032 · Cited by 317
The influence of gut microbiota on drug metabolism and toxicity
Li, H., He, J., & Jia, W. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1121234 · Cited by 278
Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics
Carmody, R. N., & Turnbaugh, P. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72335 · Cited by 268
“Studies performed decades ago showed that digoxin is inactivated by the gut-resid-ing Actinobacterium Eggerthella lenta (18), consistent with clinical reports of increased bioavailability after coadministration of digoxin and broad-spectrum antibiotics (19).”
Drug-microbiota interactions: an emerging priority for precision medicine
Zhao, Q., Chen, Y., Huang, W., Zhou, H., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01619-w · Cited by 268
The influence of the gut microbiota on the bioavailability of oral drugs
Zhang, X., Han, Y., Huang, W., Jin, M., & Gao, Z. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.09.013 · Cited by 242
Pharmacomicrobiomics: a novel route towards personalized medicine?
Doestzada, M., Vila, A. V., Zhernakova, A., Koonen, D. P. Y., Weersma, R. K., Touw, D. J., Kuipers, F., Wijmenga, C., & Fu, J. (2018) · Protein & Cell · doi:10.1007/s13238-018-0547-2 · Cited by 210
The Impact of the Gut Microbiota on Drug Metabolism and Clinical Outcome.
Enright, E. F., Gahan, C. G. M., Joyce, S. A., & Griffin, B. T. (2016) · PubMed · Cited by 202
Review: Mechanisms of How the Intestinal Microbiota Alters the Effects of Drugs and Bile Acids
Klaassen, C. D., & Cui, J. Y. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065698 · Cited by 201
Mebolism of drugs and other xenobiotics in the gut lumen and wall
Ilett, K. F., Tee, L. B. G., Reeves, P. T., & Minchin, R. F. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90036-2 · Cited by 201
Haiser, H. J., Seim, K. L., Balskus, E. P., & Turnbaugh, P. J. (2014) · Gut Microbes · doi:10.4161/gmic.27915 · Cited by 197
Experimental design and quantitative analysis of microbial community multiomics
Mallick, H., Ma, S., Franzosa, E. A., Vatanen, T., Morgan, X. C., & Huttenhower, C. (2017) · Genome Biology · doi:10.1186/s13059-017-1359-z · Cited by 192
Developing a metagenomic view of xenobiotic metabolism
Haiser, H. J., & Turnbaugh, P. J. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2012.07.009 · Cited by 186
“A large scale screening experiment of fecal isolates allowed Lindenbaum and colleagues to identify Eggerthella lenta as the sole microbe able to carry out the conversion of digoxin to dihydrodigoxin in isolation (Figure 2a) [48].”
BackgroundSmall molecule inhibitors of ROR γt: Targeting Th17 cells and other applications
Huh, J. R., & Littman, D. R. (2012) · European Journal of Immunology · doi:10.1002/eji.201242740 · Cited by 175
Oral controlled and sustained drug delivery systems
Kaur, G., Grewal, J., Jyoti, K., Jain, U. K., Chandra, R., & Madan, J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813689-8.00015-x · Cited by 165
NSAID–Gut Microbiota Interactions
Maseda, D., & Ricciotti, E. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01153 · Cited by 159
Gut microbiota-mediated drug interactions between lovastatin and antibiotics
Yoo, D.-H., Kim, I. S., Van Le, T. K., Jung, I.-H., Yoo, H. H., & Kim, D.-H. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058354 · Cited by 158
“As the impact of gut microbiota on drug metabolism has gradually been gaining recognition, the potential DDIs occurring via the interactions with microbiota metabolism studied, and the impact of gut microbes on DDIs has been discussed (Lindenbaum et al., 1981; Saha et al., 1983; Wilson and Nicholson, 2009).”
BackgroundBest practices for germ-free derivation and gnotobiotic zebrafish husbandry
(2017) · Methods in Cell Biology · doi:10.1016/bs.mcb.2016.11.005 · Cited by 157
Rengelshausen, J., Göggelmann, C., Burhenne, J., Riedel, K., Ludwig, J., Weiß, J., Mikus, G., Walter‐Sack, I., & Haefeli, W. E. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01824.x · Cited by 156
Gut microbiota modulates drug pharmacokinetics
Zhang, J., Zhang, J., & Wang, R. (2018) · Drug Metabolism Reviews · doi:10.1080/03602532.2018.1497647 · Cited by 150
Koppel, N., Bisanz, J. E., Pandelia, M.-E., Turnbaugh, P. J., & Balskus, E. P. (2018) · eLife · doi:10.7554/elife.33953 · Cited by 145
Extrinsic factors influencing gut microbes, the immediate consequences and restoring eubiosis
Bajinka, O., Tan, Y., Abdelhalim, K. A., Özdemir, G., & Qiu, X. (2020) · AMB Express · doi:10.1186/s13568-020-01066-8 · Cited by 140
Is It Time for a Metagenomic Basis of Therapeutics?
Haiser, H. J., & Turnbaugh, P. J. (2012) · Science · doi:10.1126/science.1224396 · Cited by 133
Gut Microbiome and Response to Cardiovascular Drugs
Tuteja, S., & Ferguson, J. F. (2019) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.119.002314 · Cited by 134
Tsunoda, S. M., Gonzales, C., Jarmusch, A. K., Momper, J. D., & JOSEPH, D. R. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01032-y · Cited by 129
RNA-Seq Quantification of Hepatic Drug Processing Genes in Germ-Free Mice
Selwyn, F. P., Cui, J. Y., & Klaassen, C. D. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.063545 · Cited by 122
Targeting gut microbiota for precision medicine: Focusing on the efficacy and toxicity of drugs
Feng, W., Liu, J., Ao, H., Yue, S., & Peng, C. (2020) · Theranostics · doi:10.7150/thno.47289 · Cited by 121
Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response
Scher, J. U., Nayak, R. R., Úbeda, C., Turnbaugh, P. J., & Abramson, S. B. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0395-3 · Cited by 121
The effect of gut microbiota on drug metabolism
Kang, M. J., Kim, H. G., Kim, J. S., Oh, D. G., Um, Y. J., Seo, C. S., Han, J. W., Cho, H. J., Kim, G. H., Jeong, T. C., et al. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.807798 · Cited by 120
The emerging role of the gut microbiota and its application in inflammatory bowel disease
Xiu, W., Peng, J., Cai, P., Xia, Y., Yi, C., Shang, A., Akanyibah, F. A., & Mao, F. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117302 · Cited by 121
Xenobiotics: Interaction with the Intestinal Microflora
Lu, K., Mahbub, R., & Fox, J. G. (2015) · ILAR Journal · doi:10.1093/ilar/ilv018 · Cited by 117
Metagenomic Surveys of Gut Microbiota
Mandal, R. S., Saha, S., & Das, S. (2015) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2015.02.005 · Cited by 116
Pharmacokinetic Interactions with Digoxin
Rodin, S. M., & Johnson, B. F. (1988) · Clinical Pharmacokinetics · doi:10.2165/00003088-198815040-00003 · Cited by 113
Mamic, P., Chaikijurajai, T., & Tang, W. H. W. (2020) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2020.12.001 · Cited by 107
Microbiota in Gut‐Heart Axis: Metabolites and Mechanisms in Cardiovascular Disease
Kondapalli, N. B., Katari, V., Dalal, K. K., Paruchuri, S. M., & Thodeti, C. K. (2025) · Comprehensive physiology · doi:10.1002/cph4.70024 · Cited by 107
Clinical Pharmacology of Gatifloxacin, a New Fluoroquinolone
Grasela, D. M. (2000) · Clinical Infectious Diseases · doi:10.1086/314061 · Cited by 103
The Implication of the Gut Microbiome in Heart Failure
Lupu, V. V., Răileanu, A. A., Mihai, C. M., Morariu, I. D., Lupu, A., Stârcea, I. M., Frăsinariu, O. E., Mocanu, A., Dragan, F., & Fotea, S. (2023) · Cells · doi:10.3390/cells12081158 · Cited by 98
Mooradian, A. D. (1988) · Clinical Pharmacokinetics · doi:10.2165/00003088-198815030-00002 · Cited by 98
Mechanisms of gastrointestinal microflora on drug metabolism in clinical practice
Sun, C., Chen, L., & Shen, Z. (2019) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2019.09.011 · Cited by 97
The Influence of Intestinal Tract and Probiotics on the Fate of Orally Administered Drugs
Stojančević, M., Bojić, G., Salami, H. A., & Momir, M. (2014) · Current Issues in Molecular Biology · doi:10.21775/cimb.016.055 · Cited by 97
Personalized medicine in diabetes: the role of ‘omics’ and biomarkers
Pearson, E. R. (2016) · Diabetic Medicine · doi:10.1111/dme.13075 · Cited by 94
Cometabolism of Microbes and Host: Implications for Drug Metabolism and Drug-Induced Toxicity
Li, H., & Jia, W. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.157 · Cited by 93
Mesnage, R., & Antoniou, M. N. (2020) · Current Research in Toxicology · doi:10.1016/j.crtox.2020.04.001 · Cited by 93
García-Villalba, R., Beltrán, D., Frutos-Lisón, M. D., Selma, M. V., Espín, J. C., & Tomás-Barberán, F. A. (2020) · Food & Function · doi:10.1039/d0fo01649g · Cited by 89
Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response?
Sharma, A., Buschmann, M. M., & Gilbert, J. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1437 · Cited by 86
Individual Variation in First-Pass Metabolism
Tam, Y. K. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199325040-00005 · Cited by 86
Taub, M. E., Mease, K. M., Sane, R. S., Watson, C. A., Chen, L.-F., Ellens, H. M., Hirakawa, B. P., Reyner, E. L., Jani, M., & Lee, C. A. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040816 · Cited by 84
Pharmacokinetics of Cardiovascular Drugs in Children: Inotropes and Vasopressors
Steinberg, C., & Notterman, D. A. (1994) · Clinical Pharmacokinetics · doi:10.2165/00003088-199427050-00003 · Cited by 84
The metabolic effect of gut microbiota on drugs
Xie, Y., Hu, F., Xiang, D., Lu, H., Li, W., Zhao, A., Huang, L., & Wang, R. (2020) · Drug Metabolism Reviews · doi:10.1080/03602532.2020.1718691 · Cited by 83
The functional impact of the intestinal microbiome on mucosal immunity and systemic autoimmunity
Longman, R. S., & Littman, D. R. (2015) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000190 · Cited by 82
Long, Y., & Luo, J. (2020) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2020.2998906 · Cited by 80
Sharma, A. K., Jaiswal, S. K., Chaudhary, N., & Sharma, V. K. (2017) · Scientific Reports · doi:10.1038/s41598-017-10203-6 · Cited by 80
Congestive Heart Failure in the Elderly
Luchi, R. J., Taffet, G. E., & Teasdale, T. A. (1991) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1991.tb02705.x · Cited by 79
Gut microbiome and cardiovascular disease
Zhao, Y., & Wang, Z. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000720 · Cited by 77
Holt, P. R., Atillasoy, E. O., Lindenbaum, J., Ho, S. B., Lupton, J. R., McMahon, D. J., & Moss, S. F. (1996) · Metabolism · doi:10.1016/s0026-0495(96)90020-7 · Cited by 73
Self-citationPai, M. P., Momary, K. M., & Rodvold, K. A. (2006) · Medical Clinics of North America · doi:10.1016/j.mcna.2006.06.008 · Cited by 73
Exploring the potential impact of probiotic use on drug metabolism and efficacy
Purdel, C. N., Ungurianu, A., Adam-Dima, I., & Margina, D. M. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114468 · Cited by 71
Brittain, D. C. (1987) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30802-1 · Cited by 69
Advancing gut microbiome research using cultivation
Sommer, M. O. A. (2015) · Current Opinion in Microbiology · doi:10.1016/j.mib.2015.08.004 · Cited by 71
Relationship Between the Gut Microbiome and Systemic Chemotherapy
Ervin, S. M., Ramanan, S. V., & Bhatt, A. P. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06119-3 · Cited by 67
Exploring Drug Metabolism by the Gut Microbiota: Modes of Metabolism and Experimental Approaches
Dhurjad, P., Dhavaliker, C., Gupta, K., & Sonti, R. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000669 · Cited by 66
Precision microbiota therapy for IBD: premise and promise
Nagayama, M., Gogokhia, L., & Longman, R. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2489067 · Cited by 70
Inhibition of P-glycoprotein–Mediated Efflux of Digoxin and Its Metabolites by Macrolide Antibiotics
Hughes, J., & Crowe, A. P. (2010) · Journal of Pharmacological Sciences · doi:10.1254/jphs.10109fp · Cited by 66
Mathan, V. I., Wiederman, J., Dobkin, J. F., & Lindenbaum, J. (1989) · Gut · doi:10.1136/gut.30.7.971 · Cited by 62
Self-citationDempsey, J. L., Wang, D., Siginir, G., Fei, Q., Raftery, D., Gu, H., & Cui, J. Y. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy271 · Cited by 59
Ye, Q., Shao, X., Shen, R., Chen, D., & Shen, J. (2020) · Helicobacter · doi:10.1111/hel.12713 · Cited by 59
Digoxin toxicity due to interaction of digoxin with erythromycin.
Maxwell, D. L., Gilmour-White, S. K., & Hall, M. R. (1989) · BMJ · doi:10.1136/bmj.298.6673.572 · Cited by 57
How to Determine the Role of the Microbiome in Drug Disposition
Bisanz, J. E., Spanogiannopoulos, P., Pieper, L. M., Bustion, A. E., & Turnbaugh, P. J. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.083402 · Cited by 55
Takahashi, M., Ishikawa, D., Sasaki, T., Lu, Y., Kuwahara‐Arai, K., Kamei, M., Shibuya, T., Osada, T., Hiramatsu, K., & Nagahara, A. (2018) · Journal of Applied Microbiology · doi:10.1111/jam.14167 · Cited by 55
The role of the gastrointestinal microflora in the metabolism of drugs
Shamat, M. A. (1993) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(93)90121-u · Cited by 54
The Future of Microbiome‐Based Therapeutics in Clinical Applications
Sharma, A., Das, P., Buschmann, M. M., & Gilbert, J. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1677 · Cited by 53
Gut microbiota in reductive drug metabolism
Guo, Y., Lee, H., & Jeong, H. (2020) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.04.002 · Cited by 51
Mammalian gut metabolomes mirror microbiome composition and host phylogeny
Gregor, R., Probst, M., Eyal, S., Aksenov, A. A., Sasson, G., Horovitz, I., Dorrestein, P. C., Meijler, M. M., & Mizrahi, I. (2021) · The ISME Journal · doi:10.1038/s41396-021-01152-0 · Cited by 51
Challenges and opportunities of strain diversity in gut microbiome research
Anderson, B., & Bisanz, J. E. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1117122 · Cited by 50
Past, present, and future of microbiome-based therapies
Manrique, P., Montero, I., Fernández-Gosende, M., Martínez, N., Hidalgo-Cantabrana, C., & Ríos-Covián, D. (2024) · Microbiome Research Reports · doi:10.20517/mrr.2023.80 · Cited by 51
Challenges Associated with Route of Administration in Neonatal Drug Delivery
Linakis, M. W., Roberts, J. K., Lala, A., Spigarelli, M. G., Medlicott, N. J., Reith, D. M., Ward, R. M., & Sherwin, C. M. T. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0313-z · Cited by 50
Reduction of digoxin to 20R-dihydrodigoxin by cultures of Eubacterium lentum
Robertson, L. W., Chandrasekaran, A., Reuning, R. H., Hui, J., & Rawal, B. D. (1986) · Applied and Environmental Microbiology · doi:10.1128/aem.51.6.1300-1303.1986 · Cited by 50
A case series of hospitalized patients with elevated digoxin levels
Marik, P. E., & Fromm, L. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00195-8 · Cited by 50
Introduction and Overview of Oral Controlled Release Formulation Design
Wen, H., & Park, K. (2010) · Wiley eBooks · doi:10.1002/9780470640487.ch1 · Cited by 48
Interplays between drugs and the gut microbiome
Wan, Y., & Zuo, T. (2022) · Gastroenterology report · doi:10.1093/gastro/goac009 · Cited by 48
Mythen, S. M., Devendran, S., Méndez–García, C., Cann, I., & Ridlon, J. M. (2018) · Applied and Environmental Microbiology · doi:10.1128/aem.02475-17 · Cited by 48
The Future of Pharmacogenomics: Integrating Epigenetics, Nutrigenomics, and Beyond
Shaman, J. A. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14121121 · Cited by 45
Use of digoxin for heart failure and atrial fibrillation in elderly patients
Cheng, J. W. M., & Rybak, I. (2010) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2010.10.001 · Cited by 45
Digoxin–Macrolide Drug Interaction
Bizjak, E. D., & Mauro, V. F. (1997) · Annals of Pharmacotherapy · doi:10.1177/106002809703100918 · Cited by 45
Garey, K. W., & Amsden, G. W. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.18046 · Cited by 45
Investigation of Host–Gut Microbiota Modulation of Therapeutic Outcome
Yip, L. Y., & Chan, E. C. Y. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.063750 · Cited by 43
Gemikonakli, G., Mach, J., & Hilmer, S. N. (2020) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaa047 · Cited by 43
Speckmann, B., Ehring, E., Hu, J., & Rodriguez‐Mateos, A. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2305716 · Cited by 43
Gut microbiota and the human gut physiological changes
Bajinka, O., Darboe, A., Tan, Y., Abdelhalim, K. A., & Cham, L. B. (2020) · Annals of Microbiology · doi:10.1186/s13213-020-01608-2 · Cited by 42
Metadata
- Authors
- Dobkin, J. F., Saha, J. R., Butler, V. P., Neu, H. C., & Lindenbaum, J.
- Affiliations
- Harlem Hospital Center (US)
- Columbia University (US)
- ORCID
- Saha, Jnan R.
- Venue
- Science
- Published
- 1983-04-15
- Volume
- 220
- Issue
- 4594
- Pages
- 325-327
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2083212229
- Cited by
- 259
- References
- 15
- Citations by year
- 2026: 13 · 2025: 13 · 2024: 17 · 2023: 16 · 2022: 10 · 2021: 14 · 2020: 29 · 2019: 12 · 2018: 17 · 2017: 10 · 2016: 8 · 2015: 13 · 2014: 8 · 2013: 7 · 2012: 5
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Physical Sciences › Chemistry › Organic Chemistry › Steroid Chemistry and Biochemistry
- Keywords
- digoxin, bacterial metabolism, Eubacterium lentum, cardiac glycosides, L-arginine, stool culture
- MeSH terms
- Arginine, Colon, Digoxin, Eubacterium, Feces, Humans, Oxidation-Reduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.